Start-Up Quarterly Statistics, Q4 2016
Executive Summary
A review of biopharma start-up dealmaking and financing from October through December 2016, based on data from Strategic Transactions.
You may also be interested in...
Start-Up Quarterly Statistics: 2017 Fundraising Ends Better Than It Began
But Q4 was the third sequential quarter with a decrease in financing totals. A review of biopharma start-up dealmaking and financing activity from October through December 2017, based on data from Strategic Transactions.
Pharmas Pursue Tech Deals To Speed Drug Development, Measure Outcomes
Deals for technology platforms allow more of a multiple-shots-on-goal approach as opposed to taking a risk with one or two candidates.
Sanofi's Biosimilars Deal With JHL Confirms Growing Trend In China
Sanofi is joining the biosimilars trend to tap into China through a local partnership with Taiwan's JHL Biotech, initially focusing on rituximab, a biosimilar product that has great market potential but strong competition in development by domestic peers.